Tuloxxin® Injection - Application in Cattle

reading time
Product | 29.12.2020
Tuloxxin® Injection is a new antibiotic product to complete the Huvepharma cattle antibiotic product range.

The active substance in Tuloxxin® Injection is tulathromycin, which belongs to the macrolide group of antibiotics. It differs from many macrolides and other antibiotics as it has a long duration of action, due to its unique chemical structural features (it belongs to the triamilide subclass of macrolides). 

A single subcutaneous injection (2.5 mg/tulathromycin per kg bodyweight) is sufficient for the treatment of respiratory diseases in cattle. 

Tuloxxin® is a broad-spectrum antibiotic with clinical effects against the main cattle respiratory bacteria pathogens (Mannheimia haemolyticaHistophilus somniPasturella multocidaMycoplasma bovis). These pathogens are involved in the Bovine Respiratory Disease (BRD) Complex, the most common and costly disease affecting beef cattle worldwide. 

Sensitivity of bovine respiratory pathogens

Results from a pan-European survey of antimicrobial susceptibility (susceptibility monitoring programs, VetPath, MycoPath) show high sensitivity of bovine respiratory bacteria pathogens against tulathromycin. 

Table 1. Sensitivity and resistance of European respiratory pathogens against tulathromycin

The absence or low levels of resistance verify the importance of tulathromycin as one of the antibiotics of choice for treatment against the listed bacteria species. 


Tulathromycin's pharmacokinetic (PK) behaviour is characterized by its rapid release from the injection site, fast distribution to the target tissues (lung, pulmonary epithelial lining fluid (PELF), alveolar macrophages) and high and early concentrations at the sites of pneumonia infection. Tulathromycin's lipophilic nature leads to extensive drug penetration into lung tissue and lung fluids. 

Key tulathromycin PK features, allowing single injection therapy in cattle: 

  • slow release (elimination half-life of approximately 8 days) from the lung
  • high lung and pulmonary fluid concentration over several days
  • intracellular accumulation in alveolar macrophages over long time periods (15 days)

Pharmacokinetic / Pharmacodynamic relationships

PK / Pharmacodynamic (PD) relationships are an effective tool to predict the efficacy of tulathromycin to inhibit bacterial pathogens in the BRD complex. Figure 1 shows the important role of tulathromycin lung and macrophage concentrations achieved after a single Tuloxxin® injection at a treatment dose of 2.5 mg/kg bodyweight.

Figure 1. PK / PD relationships and tulathromycin resistance in EU cattle respiratory isolates

Higher tulathromycin concentrations in lung tissue and in macrophages in pulmonary epithelial fluid were determined, more than tulathromycin MIC values for H. somniP. multocida and M. haemolytica

The tulathromycin concentrations in the lung and bovine alveolar macrophage cells exceed the MIC90 values for cattle respiratory pathogens for a prolonged time (7 days for lung, 15 days for macrophages) as shown in a cattle PK study (Cox et al., 2010). 


PK characteristics and persistence of high tulathromycin levels over longer periods are the reasons for the excellent clinical response after Tuloxxin® parenteral treatment, shown in clinical studies with natural BRD outbreaks caused by bovine bacterial and mycoplasmal pathogens.

One-shot treatment with Tuloxxin® Injection is the way forward. It is a solution for effective BRD treatment, used to maintain cattle health and welfare in the context of implementation of a responsible antimicrobial stewardship (AMS) policy. 



Cox, S.R., McLaughlin, C., Fielder, A.E. and Yancey, M.F. (2010). Rapid and prolonged distribution of tulathromycin into lung homogenate and pulmonary epithelial lining fluid of Holstein calves following a single subcutaneous administration of 2.5 mg/kg bodyweight. International Journal of Applied Research in Veterinary Medicine, Vol 8 No. 3. 129-137. 

global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us


Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.

To view all products and services, select Global from the dropdown menu or click .




North America


South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.


United States

Click here to visit the local website or close this popup to stay on the global website.

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now